Increased CCR7loPD-1hiCXCR5+CD4+ T Cells in Peripheral Blood Mononuclear Cells Are Correlated with Immune Activation in Patients with Chronic HBV Infection

Ya-Xin Huang,1,2,3 Qi-Yi Zhao,1,2,3 Li-Li Wu,1,2,3 Dong-Ying Xie,1,2,3 Zhi-Liang Gao,1,2,3 and Hong Deng1,2,3

1Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China
2Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
3Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, Guangdong 510080, China

Correspondence should be addressed to Hong Deng; dhong@mail.sysu.edu.cn

Received 16 May 2018; Revised 6 July 2018; Accepted 30 September 2018; Published 8 October 2018

1. Introduction

HBV infection remains among the most serious issues in global public health despite extensive vaccination and effective antiviral treatments. A total of 250 million people suffer from chronic hepatitis B virus (HBV) infection worldwide, most of whom live in Africa and Asia [1, 2]. HBV-associated diseases, such as liver failure, cirrhosis, and hepatocellular carcinoma, contribute to the deaths of 1 million people per year [3].

Our understanding of the natural history of HBV infection and the resultant disease is continuously improving. Complex interactions between the viral and host immune systems participate in disease progression, allowing for HBV penetration into host cells, formation of persistence, and chronization of HBV infection or complete elimination of the virus [4, 5]. Although various clinical and experimental investigations have helped diagnose, treat, and prevent hepatitis B, the exact mechanism underlying the host immune reactions remains unclear.

According to the complex interactions between the virus, hepatocytes, and the host immune system, the natural course of chronic HBV infection is usually stratified into 4 phases, the immune tolerant (IT) phase, the immune clearance (IC) phase, the low replicative (LR) phase, and the reactivation (RA) phase [6].

Proteins of partial HBV can modulate immunity and enable immune escape. In the course of the disease, a better prognosis can be achieved if HBeAg seroconversion occurs early. The prevalence of cirrhosis and hepatocellular cancer...
carcinoma in patients during this time declines. In addition, HBsAg loss and/or seroconversion is considered the ideal goal of treatment and a milestone in effective treatment response in both HBeAg-positive and HBeAg-negative patients [7].

The production of antibodies plays an indispensable role in both HBeAg and HBsAg seroconversion[8]. Circulating CXCR5^CD4^+ T cells, which are the counterpart of T follicular helper (Tfh) cells in the peripheral blood, have been reported to play a significant role in accelerating HBeAg seroconversion in chronic HBV-infected patients [9].

Tfh cells are considered to be a subset of CD4^+ T cells in secondary lymphoid tissues that express CXC-chemokine receptor 5 (CXCR5), which helps Tfh cells localize to B cell follicles. Studies have reported that CXCR5^CD4^+ T cells are more efficient than CXCR5^CD4^+ T cells in inducing B cells to secrete antibodies and switch antibody classes [10–12]. Tfh cells coexpress programmed cell death protein 1 (PD-1) and inducible T cell co-stimulator (ICOS) and down-regulate CC-chemokine receptor 7 (CCR7) [13–15]. Several investigations have found elevated expression of circulating CXCR5^CD4^+ T cells in patients with autoimmune diseases (such as systemic lupus erythematosus (SLE) and Sjogren’s syndrome)[16,17] and infectious diseases (such as hepatitis B and C)[18,19]. However, He J et al. found no increase in the frequency of circulating CXCR5^CD4^+ T cells in SLE patients [20], which was inconsistent with previous investigations. In addition, a study showed that there was no difference in the circulating CXCR5^CD4^+ T cell frequency between healthy controls and HCV patients. Interestingly, this study also found that CXCR5^CD4^+ T cells were efficient in supporting B cell responses [21]. Based on current evidence, there is no clear correlation between the activity of CXCR5^CD4^+ T cells and their frequency in peripheral blood.

Tfh cells are comprised of various subsets with different phenotypes and functions [22]. He J et al. reported that CCR7^hi^PD-1^lo^CXCR5^CD4^+ T cells have a partial Tfh effector phenotype exhibiting active Tfh differentiation in lymphoid tissues. In contrast, the CCR7^hi^PD-1^hi^ Tfh subset has a resting phenotype [20]. Studies in mice found that CXCR5^hi^PD-1^lo^ germinal center Tfh cells likely downregulate CXCR5, PD-1, and BCL-6, re-express CCR7, IL-7Rα, and CD62L, and thus differentiate into memory cells and persist for a long time [22,23]. IL-7 possibly increases the level of CXCR5^CD4^+ T cells in patients [24]. Studies investigating cystic echinococcosis also reported that CCR7^hi^PD-1^lo^CXCR5^CD4^+ T cells were increased in patients [25].

The CCR7^hi^PD-1^hi^ and CCR7^hi^PD-1^lo^ Tfh subsets in the peripheral blood have not been comprehensively investigated during the complex immunologic progression of chronic HBV infection. We hypothesize that these two Tfh subsets play a larger role in the immune response of chronic HBV infection than Tfh cells, containing multifarious subsets. The objective of this study was to detect the frequencies of CCR7^lo^PD-1^hi^CXCR5^CD4^+ T cells and CCR7^hi^PD-1^lo^CXCR5^CD4^+ T cells in peripheral blood mononuclear cells (PBMCs) from patients with chronic HBV infection and compare these frequencies to those in non-HBV infected controls. Furthermore, the correlations between the frequencies of the two subsets and alanine transaminase (ALT), which is the consequence of HBV replication, and the HBsAg level were evaluated. These findings provide new insights into the correlation between the frequencies of the two CXCR5^CD4^+ T subsets and the immune reaction in chronic HBV infection.

2. Materials and Methods

2.1. Patients and Controls. A total of 77 patients with chronic HBV infection were recruited from the Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) for this cross-sectional study. These patients were HBsAg-seropositive for longer than 6 months. The patients were divided into immune tolerant (IT) phase group (n=19), immune clearance (IC) phase group (n=20), low replicative (LR) phase group (n=18), and reactivation (RA) phase group (n=20) according to the Asian Pacific Association for the Study of Liver guidelines [6]. In addition, 20 healthy individuals were enrolled from the physical examination center. All healthy individuals were non-HBV infected, HCV infected, or HIV infected and tested normal for ALT and aspartate aminotransferase (AST).

The exclusion criteria for this study included coinfection with hepatitis viruses A, C, D, or E or HIV. Patients with autoimmune diseases, drug-induced liver injury, decompensated or compensated cirrhosis, malignant comorbidities within the prior 5 years, or previous antiviral or immunomodulatory drug treatments were also excluded.

This study was approved by the Human Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) and conducted in accordance with the Declaration of Helsinki guidelines. All subjects provided written informed consent before collecting the blood samples.

2.2. Peripheral Blood Mononuclear Cell Separation. Peripheral venous blood samples were collected from all subjects into 5 mL tubes containing EDTA as the anticoagulant. Within 4 hours of the collection, the PBMCs were separated from the samples by Ficoll separation (Axis-Shield PoC AS, Oslo, Norway). Approximately 5 × 10^6 PBMCs were collected from each sample and frozen at -80°C until analysis.

2.3. Analysis of Cell Surface Molecule Expression by Flow Cytometry. The cells were thawed and incubated at 37°C and 5% CO₂ in RPMI-1640 with 10% FCS (cell culture media) for 4 hours. Then, the cells were stained with anti-CD3 FITC (clone:SK7, eBioscience, San Diego, CA, USA), anti-CD4 eFluor® (clone: OKT4, eBioscience, San Diego, CA, USA), anti-CXCR5 APC (clone: MU5UBEE, eBioscience, San Diego, CA, USA), anti-PD-1 PE-Cy7 (clone: J105, eBioscience, San Diego, CA, USA), anti-CCR7 PE (clone: 3D12, eBioscience, San Diego, CA, USA), anti-ICOS PE (clone: 10G12, eBioscience, San Diego, CA, USA), and isotype antibodies (eBioscience, San Diego, CA, USA). The cells were washed, and the marker expression was detected by flow cytometry (Beckman Gallios Coulter, Inc., CA, USA). The samples...
Table 1: Clinical characteristics of the patients with chronic HBV infection and healthy controls.

|                        | Patients | HC | p-value |
|------------------------|----------|----|---------|
| Subjects, n            | 77       | 20 |         |
| Gender, males/females  | 45/32    | 10/10 | 0.499  |
| Age, y                 | 35(18-71)| 27(18-52)| 0.053  |
| ALT, IU/L              | 75(15-942)| 15(7-31)| <0.001 |
| AST, IU/L              | 51(13-915)| 14.5(7-34)| <0.001 |
| HBV DNA, log10 IU/mL   | 6.72(0-8.38)| NA |         |
| HBsAg, log10 IU/mL     | 3.50(1.30-4.72)| NA |         |
| HBeAg, positive/negative, n | 39/38 | 0/20 | <0.001 |
| ALT, elevated/normal, n | 40/37   | 0/20 | <0.001 |

Abbreviations: ALT: alanine transaminase; AST: aspartate aminotransferase; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B s antigen; HBV: hepatitis B virus; HC: healthy controls; NA: not applicable.
(a) Values are expressed as the median (minimum-maximum) for age, ALT, AST, and HBV DNA.
(b) HBV DNA<100 was treated as 0 log10 IU/ml.

Table 2: Clinical characteristics of 4 subgroups of patients with chronic HBV infection.

|        | IT       | IC       | LR       | RA       | p-value |
|--------|----------|----------|----------|----------|---------|
| Subjects, n | 19       | 20       | 18       | 20       |         |
| Gender, males/females | 10/9   | 12/8     | 11/7     | 12/8     | 0.950   |
| Age, y | 29(18-52) | 29(18-56) | 41.5(18-71) | 42(24-65) | 0.002   |
| ALT, IU/L | 27(16-38) | 293(85-939) | 25.5(15-34) | 332(57-942) | <0.001   |
| AST, IU/L | 28(13-38) | 129(51-491) | 22(19-34) | 177.5(39-915) | <0.001   |
| HBV DNA, log10 IU/mL | 7.87(6.45-8.38) | 7.76(3.72-8.23) | 2.36(0-3.20) | 5.51(2.00-8.23) | <0.001   |
| HBsAg, log10 IU/mL | 4.557(3.495-4.54) | 3.85(2.85-4.60) | 2.69(1.35-3.53) | 3.32(1.30-4.61) | <0.001   |
| HBeAg, positive/negative, n | 19/0   | 20/0     | 0/18     | 0/20     | <0.001   |
| ALT, elevated/normal, n | 0/19   | 20/0     | 0/18     | 20/0     | <0.001   |

(a) Values are expressed as median (minimum-maximum) for age, ALT, AST, and HBV DNA.
(b) HBV DNA<100 was treated as 0 log10 IU/ml.
(c) HBsAg<20 was treated as 20.

underwent detection within 4 hours. The data were analyzed using FlowJo 10.0 (Tree Star Inc., Ashland, Or, USA).

2.4. Laboratory Indices. The quantitative values of the following indices were tested by Elecsys (Roche Diagnostics GmbH, Mannheim, Germany) at the noted reference ranges: HBsAb, 0-10 IU/L; HBeAg, <1.0 cut-off index (COI); HBeAb, >1.0 COI; and HBcAb, >1.0 COI. The HBsAg titers were quantified using Elecsys HBsAg II Quant reagent kits (Roche Diagnostics, Indianapolis, IN, USA). The detection limit of the kit was 20 IU/ml. The HBV-DNA levels were quantitated by performing real-time quantitative polymerase chain reaction (Daan GENE, Guangzhou, China). The detection limit of the assay was 100 IU/mL. The biochemical indices were detected using an autobiochemical analyzer (HITACHI 7180, Tokyo, Japan). ALT and AST were within the reference ranges of 3-35 U/L and 13-35 U/L, respectively.

2.5. Statistical Analysis. All statistical analyses were performed using SPSS 24.0 software for Windows (SPSS Inc., Chicago, IL, USA), and the data were presented as the median (minimum, maximum) (age, ALT, AST, HBV DNA, and HBsAg) or the mean ± standard deviation (frequencies of cells). Multiple comparisons were performed using nonparametric Kruskal-Wallis tests with Bonferroni correction for the sub-analyses. The statistical significance between two groups was determined by performing a Mann–Whitney U test. The correlation between the CCR7hiPD-1hiCXCR5+CD4+ T cell frequency and clinical parameters was examined by performing Spearman’s rank correlation. All statistical tests were two-tailed. The differences were considered statistically significant at p<0.050.

3. Results

3.1. Study Subjects’ Characteristics. The subjects in this study included 77 treatment-naive patients who had been HBsAg-positive for longer than 6 months and 20 healthy volunteers with normal ALT and AST (Table 1). According to the immune phases, the 77 HBV-infected patients were further classified as follows: IT phase (n=19), IC phase (n=20), LR phase (n=18), and RA phase (n=20) (Table 2).
Wallis tests, although no significant difference was observed vs 11.94 ± 4.87% in the healthy controls (14.92 ± 2.95%, p = 0.018, Figure 2(b)). In addition, the frequency of the CCR7loPD-1hi CXCR5+CD4+ T cells was lower in the patients with chronic HBV infection, but not significantly (p = 0.169) (Figure 3(b)). Nevertheless, the frequency of CCR7loPD-1hi CXCR5+CD4+ T cells was significantly higher in the patients than in the healthy controls (14.92 ± 4.87% vs 12.23 ± 2.95%, p = 0.018, Figure 2(b)). In addition, the frequency of the CCR7loPD-1hi CXCR5+CD4+ T cells was lower in the patients with chronic HBV infection, but not significantly (p = 0.715).

We further investigated the association among the frequencies of the CXCR5+CD4+ T cells, CCR7loPD-1hi Tfh subset, and HBV by stratifying the patients according to their immune status (IT, IC, LR, or RA). Based on the Kruskal-Wallis tests, although no significant difference was observed in the frequency of the CXCR5+CD4+ T cells among the 4 groups (p = 0.885), differences in the CCR7loPD-1hi Tfh subset were observed in the groups (p < 0.001). After conducting the Bonferroni correction, we found that the frequency of CCR7loPD-1hi CXCR5+CD4+ T cells was higher in the IC group (18.42 ± 3.08) than in the IT group (11.94 ± 2.87%, p = 0.001) and LR group (13.65 ± 4.93%, p = 0.031). In addition, the frequency of the CCR7loPD-1hi CXCR5+CD4+ T cells was higher in the RA group than in the IT group (16.03 ± 5.37% vs 11.94 ± 2.87%, p = 0.030, Figure 3(a)). Although frequency of CCR7loPD-1hi CXCR5+CD4+ T cells of IT group was lower than LR group, the difference was not significant (11.94 ± 2.86% vs 13.64 ± 4.93%, p = 0.169) (Figure 3(b)).

The comparison between people with raised ALT and normal ALT has been conducted and the difference was significant (16.91 ± 4.77% vs 12.58 ± 3.68%, p < 0.001). The frequency of the CCR7loPD-1hi CXCR5+CD4+ T cells was higher in the raised ALT group relative to the normal ALT group (Figure 4).

3.3. Correlation between the Two Tfh Cell Subsets and Clinical Parameters of the Chronic HBV Infected Patients. The correlations between the CCR7loPD-1hiCXCR5+CD4+ T cell and the CCR7loPD-1hiCXCR5+CD4+ T cell populations in the PBMCs and the patients’ ALT, HBV DNA load, HBsAg level, age, and gender were investigated. Based on Spearman’s rank correlation analysis, there was a positive correlation between the CCR7loPD-1hiCXCR5+CD4+ T cell populations and levels of ALT (r = 0.370, p = 0.001, Figure 5(a)). However, the correlation was weak and not convincing enough. Besides, no correlation was observed between the frequency of the CCR7loPD-1hiCXCR5+CD4+ T cells and the ALT levels (r = -0.143, p = 0.050). Furthermore, CCR7loPD-1hiCXCR5+CD4+ T cells (r = -0.028, p = 0.005, Figure 5(b)) or
Figure 2: Frequencies of CXCR5⁺CD4⁺ T cells and CCR7⁻PD-1⁺CXCR5⁺CD4⁺ T cells in chronic HBV patients (n=77) and healthy controls (n=20). (a) Frequency of CXCR5⁺CD4⁺ among all CD4⁺CD3⁺ cells. (b) Frequency of CCR7⁻PD-1⁺CXCR5⁺CD4⁺ among all CXCR5⁺CD4⁺CD3⁺ cells. Horizontal lines show the median.

Figure 3: Frequency of CCR7⁻PD-1⁺CXCR5⁺CD4⁺ T cells among all CXCR5⁺CD4⁺CD3⁺ cells in the patients with chronic HBV infection and between IT group and LR group. (a) Differences between the IT group (n=19) and IC group (n=20), between the IT group and RA group (n=20), and between the IC group and LR group (n=18) were significant. Statistical comparison was performed using a Bonferroni correction. (b) Difference between the IT group (n=19) and LR group (n=18) was not significant (p=0.169). The horizontal lines show the median.

CCR7⁻PD-1⁺CXCR5⁺CD4⁺ T cells (r=-0.160, p>0.005) had no correlation with HBV DNA. Neither of the CCR7⁻PD-1⁺ (r=0.008, p>0.050, Figure 5(c)) or the CCR7⁻PD-1⁻ Tfh subsets (p>0.050) were correlated with HBsAg.

Although a negative correlation was observed between the CCR7⁻PD-1⁺CXCR5⁺CD4⁺ T cells and age in the patients with chronic HBV infection (r=-0.264, p=0.020), no evidence was found supporting a correlation between the CCR7⁻PD-1⁺CXCR5⁺CD4⁺ T cells and age among the patients (r=0.182, p=0.114). Further analysis showed significant difference in ages among the patients (p=0.002), and younger subjects were more likely to be in the IT and IC
Table 3: Correlations between frequency of CCR7\textsuperscript{lo}PD-1\textsuperscript{hi}CXCR5\textsuperscript{+}CD4\textsuperscript{+} T cells and clinical characteristics in 4 subgroups of patients with chronic HBV infection.

| Group/Clinical characteristics | ALT(U/L) | HBV DNA, log10 IU/ml | HBsAg, log10 IU/ml |
|---------------------------------|----------|-----------------------|-------------------|
|                                 | r-value  | p-value               | r-value           | p-value   | r-value  | p-value   |
| IT                              | 0.022    | 0.930                 | 0.238             | 0.326     | -0.300   | 0.213     |
| IC                              | -0.149   | 0.530                 | -0.145            | 0.543     | 0.192    | 0.461     |
| LR                              | -0.206   | 0.412                 | 0.145             | 0.567     | 0.220    | 0.381     |
| RA                              | 0.189    | 0.425                 | -0.222            | 0.348     | -0.273   | 0.258     |

Table 4: Correlations between frequency of CCR7\textsuperscript{hi}PD-1\textsuperscript{lo}CXCR5\textsuperscript{+}CD4\textsuperscript{+} T cells and clinical characteristics in 4 subgroups of patients with chronic HBV infection.

| Group/Clinical characteristics | ALT(U/L) | HBV DNA, log10 IU/ml | HBsAg, log10 IU/ml |
|---------------------------------|----------|-----------------------|-------------------|
|                                 | r-value  | p-value               | r-value           | p-value   | r-value  | p-value   |
| IT                              | -0.069   | 0.780                 | -0.344            | 0.149     | -0.067   | 0.784     |
| IC                              | 0.171    | 0.470                 | -0.384            | 0.095     | 0.235    | 0.363     |
| LR                              | 0.065    | 0.797                 | -0.072            | 0.777     | -0.156   | 0.536     |
| RA                              | 0.287    | 0.220                 | 0.087             | 0.716     | 0.055    | 0.822     |

HBeAg seroconversion, led by viral and host immunity, is essential for the progression of chronic HBV infection, which is associated with a reduced risk of progressive liver inflammation, liver cirrhosis and liver cancer [6, 26]. In the natural history of chronic HBV infection, patients who have successfully undergone seroconversion usually become inactive HBsAg carriers with positive anti-HBeAg in the blood [27, 28]. A high frequency of circulating CXCR5\textsuperscript{+}CD4\textsuperscript{+} T cells has been shown to promote HBeAg seroconversion in chronic HBV patients [7].

The main function of Tfh cells is to support B cell maturation and differentiation. Tfh cells and B cells repeatedly intimately interact in the germinal center, where Tfh cells deliver important survival and differentiation signals to B cells that participate in the affinity, antibody isotype class, and potency of the ensuing antibody response [29]. Nevertheless, various studies have reported conflicting results. Many research studies have found increased expression of circulating Tfh cells in SLE, but no increase in the frequency of circulating CXCR5\textsuperscript{+}CD4\textsuperscript{+} T cells has also been reported in a study investigating SLE [20].

Our study found that the circulating CXCR5\textsuperscript{+}CD4\textsuperscript{+} T cell frequency was higher, but not significantly, in patients with chronic HBV infection than in non-HBV infected individuals. This finding is inconsistent with several former studies. The frequency of the CXCR5\textsuperscript{+}CD4\textsuperscript{+} T cells was not accurate enough to describe the difference in the immune response between chronic HBV infected patients and healthy people.

Heterogeneity is observed in Tfh cells [30]. According to the CCR7 and PD-1 expression on the cell surface, two major subsets were clearly identified within the circulating CXCR5\textsuperscript{+}CD4\textsuperscript{+} T cells. A study in repeated implantation failure reported the proportion of CCR7\textsuperscript{lo}PD-1\textsuperscript{hi}CXCR5\textsuperscript{+}CD4\textsuperscript{+} T cells was positively correlated with IL-21[31]. Another study found IL-21 was positively correlated with CCR7\textsuperscript{hi}PD-1\textsuperscript{hi} Tfh subset in transitional phase of Cystic echinococcosis[25]. IL-21 is the main cytokine secreted by Tfh cells, reported as
a critical immunomodulatory cytokine with various effects on all populations of lymphocytes. It can promote Tfh cells differentiation, regulate B cells differentiation and proliferation, induce plasma cell differentiation and immunoglobulin production[32]. Our investigation demonstrated that the frequency of the CCR7^lo^PD-1^hi^ subset was increased in the chronic HBV infected patients and positively correlated with ALT on a weak level. Most peripheral CXCR5^+^CD4^+^ T cells are resting cells, and a very small population expressing ICOS and very high levels of PD-1 are activated cells [33]. He J et al showed that the CCR7^lo^PD-1^hi^ subset had a Tfh precursor phenotype, whereas the phenotype of the CCR7^hi^PD-1^lo^ subset was characteristic of resting cells [20].

PD-1 is a negative regulatory molecule that becomes upregulated on activated T cells, B cells, monocytes, natural killer cells and dendritic cells and is particularly highly expressed on Tfh cells. The PD-1 ligands, i.e., PD-L1 and PD-L2, are extensively expressed on various cells, including T cells, B cells, dendritic cells and macrophages [34, 35]. CCR7 is a homing molecule expressed on the T cell surface and is essential for the migration of naive T cells through specialized high endothelial venules (HEVs). In addition, B cells exploit CCR7 to efficiently enter lymphoid nodes[36–38].

In our study, a stronger immune response was observed in the chronic HBV infected patients with a higher frequency of the CCR7^lo^PD-1^hi^ Tfh subset compared to the healthy controls. We hypothesize that the CCR7^lo^PD-1^hi^ Tfh subset, as an effector phenotype, may contribute to the immune response in chronic HBV infection. Furthermore, in chronic HBV infection, the frequency of the CCR7^lo^PD-1^hi^ Tfh subset is higher in the IC phase than in the IT and LR phases, suggesting that CCR7^lo^PD-1^hi^CXCR5^+^CD4^+^ T cells may indicate the level of the immune response more precisely than general CXCR5^+^CD4^+^ T cells and are related to immune status. This hypothesis was further supported by the higher frequency of the CCR7^lo^PD-1^hi^ Tfh subset in the RA phase than in the IT phase. However, there was no significant difference of frequency of CCR7^lo^PD-1^hi^ Tfh subset between IT and LR group was observed. More investigation should be complemented.

Currently, the indications for antiviral treatment in chronic HBV infection are mainly based on a combination of the following three criteria: HBV DNA load, ALT levels, and severity of liver disease [6]. By preventing the progression of liver disease and early liver-related deaths, timely and valid therapy could be highly beneficial for improving quality of

**Figure 5:** Correlations between frequency of CCR7^lo^PD-1^hi^CXCR5^+^CD4^+^ T cells and clinical indices. (a) Correlation between frequency of CCR7^lo^PD-1^hi^ Tfh cells and ALT level (r=0.370, p=0.001). (b) Correlation between frequency of CCR7^lo^PD-1^hi^ Tfh cells and HBV DNA load (p>0.05). (c) Correlation between frequency of CCR7^lo^PD-1^hi^ Tfh cells and HBsAg (p>0.05). Statistical comparison was performed using Spearman’s rank correlation analysis.
life and survival [39]. We speculate that the frequency of the CCR7loPD-1hiTh subset in the blood, which was correlated to the immune status in chronic HBV infection, may help physicians determine when to initiate antiviral treatment. Certainly, further investigations are needed to study factors influencing the frequency of CCR7loPD-1hiCXCR5+CD4+ T cells.

5. Conclusion

In conclusion, the CCR7loPD-1hiCXCR5+CD4+ T cell frequency is higher in patients with chronic HBV infection than in healthy individuals and is positively correlated with serum ALT levels in patients, indicating that CCR7loPD-1hiCXCR5+CD4+ T cells may be involved in HBV-related immune responses. Moreover, different frequencies of CCR7loPD-1hiCXCR5+CD4+ T cells are observed in patients at different immune phases. These findings might improve our understanding of the immunological pathogenesis of chronic HBV infection and may provide a novel indication for antiviral treatment.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors would like to express sincere thanks to all subjects enrolled in this study. This study was supported by the Science and Technology Project of Guangdong Province (no.2013B021800209).

References

[1] J. J. Ott, J. Horn, G. Krause, and R. T. Mikolajczyk, “Time trends of chronic HBV infection over prior decades – A global analysis,” *Journal of Hepatology*, vol. 66, no. 1, pp. 48–54, 2017.

[2] C. Stasi, C. Silvestri, and F. Voller, “Emerging Trends in Epidemiology of Hepatitis B Virus Infection,” *Journal of Clinical and Translational Hepatology*, vol. 5, no. 3, pp. 272–276, 2017.

[3] G. S. Burns and A. J. Thompson, “Viral hepatitis B: Clinical and epidemiological characteristics,” *Cold Spring Harbor Perspectives in Medicine*, vol. 4, no. 12, Article ID a024935, 2014.

[4] M. Isohara and Y. Tanaka, “Immunobiology of hepatitis B virus infection,” *Hepatology Research*, vol. 45, no. 2, pp. 179–189, 2015.

[5] I. P. Balmasova, N. D. Yushchuk, O. A. Mynbaev et al., “Immunopathogenesis of chronic hepatitis B,” *World Journal of Gastroenterology*, vol. 20, no. 39, pp. 14156–14171, 2014.

[6] S. K. Sarin, M. Kumar, G. K. Lau et al., “Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update,” *Hepatology International*, vol. 10, no. 1, pp. 1–98, 2016.

[7] WHO, *Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection*, 2015.

[8] J. F. Wu and M. H. Chang, “Natural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impacts,” *Journal of Biomedical Science*, vol. 22, p. 92, 2015.

[9] Y. Li, S. Ma, L. Tang et al., “Circulating chemokine (C-X-C Motif) receptor 5+CD4+ T cells benefit hepatitis B antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection,” *Hepatology*, vol. 58, no. 4, pp. 1277–1286, 2013.

[10] C. S. Ma and T. G. Phan, “Here, there and everywhere: T follicular helper cells on the move,” *The Journal of Immunology*, vol. 152, no. 3, pp. 382–387, 2017.

[11] H. Qi, “T follicular helper cells in space-time,” *Nature Reviews Immunology*, vol. 16, no. 10, pp. 612–625, 2016.

[12] Y. Zhu, L. Zou, and Y.-C. Liu, “T follicular helper cells, T follicular regulatory cells and autoimmunity,” *International Immunology*, vol. 28, no. 4, pp. 173–179, 2016.

[13] H. Ueno, “Human Circulating T Follicular Helper Cell Subsets in Health and Disease,” *Journal of Clinical Immunology*, vol. 36, no. 1, pp. 34–39, 2016.

[14] C. S. Ma and E. K. Deenick, “The circulating life of a memory T follicular helper cell,” *Clinical & Translational Immunology*, vol. 6, no. 5, p. e141, 2017.

[15] A. Asrir, M. Aloulou, M. Gador, C. Pérals, and N. Fazilleau, “Interconnected subsets of memory follicular helper T cells have different effector functions,” *Nature Communications*, vol. 8, no. 1, p. 847, 2017.

[16] S. Kubo, S. Nakayamada, M. Yoshikawa et al., “Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients,” *Arthritis & Rheumatology*, vol. 69, no. 10, pp. 2029–2037, 2017.

[17] M. Sawaf, H. Dumortier, and F. Monneaux, “Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?” *Journal of Immunology Research*, vol. 2016, Article ID 5767106, 13 pages, 2016.

[18] G. Xibing, Y. Xiaojuan, W. Juanhua, and H. Zhong, “Relationship between HBV genotypes B, C and follicular helper T cells in patients with chronic hepatitis B and its significance,” *Hepatitis Monthly*, vol. 13, no. 1, p. e6221, 2013.

[19] F.-Y. Kong, B. Feng, H.-H. Zhang et al., “CD4+CXCR5+ T cells activate CD27+IgG+ T cells via IL-21 in patients with hepatitis C virus infection,” *Hepatobiliary & Pancreatic Diseases International*, vol. 15, no. 1, pp. 55–64, 2016.

[20] J. He, L. M. Tsai, Y. Leong et al., “Circulating precursor CCR7PD-1hiCXCR5hiCD4hi T cells indicate th cell activity and promote antibody responses upon antigen reexposure,” *Immunity*, vol. 39, no. 4, pp. 770–781, 2013.

[21] M. Spaan, K. Kreefft, G. N. De Graav et al., “CD4+CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses,” *Journal of Hepatology*, vol. 62, no. 2, pp. 303–310, 2015.

[22] S. G. Tangye, C. S. Ma, R. Brink, and E. K. Deenick, “The good, the bad and the ugly—T_{FH} cells in human health and disease,” *Nature Reviews Immunology*, vol. 13, no. 6, pp. 412–426, 2013.

[23] M. Pepper, A. J. Pagán, B. Z. Igárytá, J. J. Taylor, and M. K. Jenkins, “Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells,” *Immunity*, vol. 35, no. 4, pp. 583–595, 2011.
[24] H. Zhong, G. Xibing, D. Yaping et al., “Interleukin-7 in patients with chronic hepatitis B may have effect on T follicular helper cells and specific cellular immunity,” *Hepatitis Monthly*, vol. 16, no. 9, p. e3668, 2016.

[25] F. Zhang, N. Pang, Y. Zhu et al., “CCR7⁺PD-1⁺ CXCR5⁺ CD4⁺ T cells are positively correlated with levels of IL-21 in active and transitional cystic echinococcosis patients,” *BMC Infectious Diseases*, vol. 15, p. 457, 2015.

[26] A. Tawada, T. Kanda, and O. Yokosuka, “Current and future directions for treating hepatitis B virus infection,” *World Journal of Hepatology*, vol. 7, no. 11, pp. 1541–1552, 2015.

[27] S. Ohkoshi, H. Hirono, K. Watanabe, K. Hasegawa, K. Kamimura, and M. Yano, “Natural regression of fibrosis in chronic hepatitis B,” *World Journal of Gastroenterology*, vol. 22, no. 24, pp. 5459–5466, 2016.

[28] S.-W. Ma, X. Huang, Y.-Y. Li et al., “High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B,” *Journal of Hepatology*, vol. 56, no. 4, pp. 775–781, 2012.

[29] B. T. Schultz, J. E. Teigler, F. Pissani et al., “Circulating HIV-Specific Interleukin-21⁺CD4⁺ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions,” *Immunity*, vol. 44, no. 1, pp. 167–178, 2016.

[30] S. Eivazi, S. Bagheri, M. S. Hashemzadeh et al., “Development of T follicular helper cells and their role in disease and immune system,” *Biomedicine & Pharmacotherapy*, vol. 84, pp. 1668–1678, 2016.

[31] Q. Gong, Y. Zhu, N. Pang et al., “Increased levels of CCR7⁺PD-1⁺ CXCR5⁺ CD4⁺ T cells, and associated factors Bcl-6, CXCR5, IL-21 and IL-6 contribute to repeated implantation failure,” *Experimental and Therapeutic Medicine*, vol. 14, no. 6, pp. 5931–5941, 2017.

[32] S. G. Tangye, “Advances in IL-21 biology—enhancing our understanding of human disease,” *Current Opinion in Immunology*, vol. 34, pp. 107–115, 2015.

[33] H. Ueno, “T follicular helper cells in human autoimmunity,” *Current Opinion in Immunology*, vol. 43, pp. 24–31, 2016.

[34] B. T. Fife and K. E. Pauken, “The role of the PD-1 pathway in autoimmunity and peripheral tolerance,” *Annals of the New York Academy of Sciences*, vol. 1217, no. 1, pp. 45–59, 2011.

[35] S. Muenst, S. D. Soysal, A. Tzankov, and S. Hoeller, “The PD-1/PD-L1 pathway: Biological background and clinical relevance of an emerging treatment target in immunotherapy,” *Expert Opinion on Therapeutic Targets*, vol. 19, no. 2, pp. 201–211, 2015.

[36] J. Lv, L. Li, W. Li et al., “Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis,” *Journal of Neuroimmunology*, 2018.

[37] P. Belikan, U. Bühler, C. Wolf et al., “CCR7 on CD4⁺ T Cells Plays a Crucial Role in the Induction of Experimental Autoimmune Encephalomyelitis,” *The Journal of Immunology*, vol. 200, no. 8, pp. 2554–2562, 2018.

[38] A. S. Jørgensen, M. M. Rosenkilde, and G. M. Hjortø, “Biased signaling of G protein-coupled receptors – From a chemokine receptor CCR7 perspective,” *General and Comparative Endocrinology*, vol. 258, pp. 4–14, 2018.

[39] M. Viganò, G. Grossi, A. Loglio, and P. Lampertico, “Treatment of hepatitis B: Is there still a role for interferon?” *Liver International*, vol. 38, pp. 79–83, 2018.